Ensysce Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.53next fiscal year
Monitoring Framework
Key Performance Indicators
Pivotal PF614-301 Phase 3 Pain Trial Enrollment Progress Quarterly50.0Target: 100% of interim enrollment target
Federal Grant Funding Revenue Quarterly961KTarget: Full utilization of multi-year NIDA awards
Research and Development (R&D) Expenses Quarterly3.3MTarget: Optimized clinical trial spend
Watch Items
- Nasdaq Stockholders' Equity Requirement ComplianceTrigger: Stockholders' equity below $2.5 million (deficit of -$669,012 as of March 31, 2026)Action: Submit a compliance plan to Nasdaq by July 6, 2026, and execute capital-raising or strategic transactions to restore equity.
- Cash Runway and Liquidity SqueezeTrigger: Cash balance falling to $745,482 as of March 31, 2026Action: Utilize the remaining tranches of the $20 million convertible preferred stock facility and secure additional non-dilutive grant funding.
- Board Review of Strategic AlternativesTrigger: Formal launch of strategic review processAction: Evaluate potential partnerships, licensing deals, or merger opportunities to maximize shareholder value and fund clinical programs.
Research as of 20 Jun 2026